Ausgabe 3/2014
Inhalt (24 Artikel)
Autophagy, a novel target for chemotherapeutic intervention of thyroid cancer
Le-chen Li, Guo-dong Liu, Xin-jie Zhang, Yan-bo Li
A phase II trial of erlotinib as maintenance treatment after concurrent chemoradiotherapy in stage III non-small-cell lung cancer (NSCLC): a Galician Lung Cancer Group (GGCP) study
J. Casal Rubio, J. L. Fírvida-Pérez, M. Lázaro-Quintela, F. J. Barón-Duarte, G. Alonso-Jáudenes, L. Santomé, F. J. Afonso-Afonso, M. Amenedo, G. Huidobro, B. Campos-Balea, M. D. López-Vázquez, S. Vázquez
Pharmacokinetics of liposomal-encapsulated and un-encapsulated vincristine after injection of liposomal vincristine sulfate in beagle dogs
Jie Zhong, Wenxue Mao, Rong Shi, Peng Jiang, Qian Wang, Rong Zhu, Tianming Wang, Yueming Ma
Phase 1b study of safety, tolerability and efficacy of R1507, a monoclonal antibody to IGF-1R in combination with multiple standard oncology regimens in patients with advanced solid malignancies
Daruka Mahadevan, Gregory Ryan Sutton, Rafael Arteta-Bulos, Chris J. Bowden, Paul J. E. Miller, Rachel Elizabeth Swart, Mark S. Walker, Paul Haluska, Pamela N. Munster, John Marshall, Omid Hamid, Razelle Kurzrock
Extraction of tamoxifen and its metabolites from formalin-fixed, paraffin-embedded tissues: an innovative quantitation method using liquid chromatography and tandem mass spectrometry
Ella S. M. Ng, S. Bill Kangarloo, Mie Konno, Alexander Paterson, Anthony M. Magliocco
A phase I pharmacodynamic trial of sequential sunitinib with bevacizumab in patients with renal cell carcinoma and other advanced solid malignancies
Justine Yang Bruce, Jill M. Kolesar, Hans Hammers, Mark N. Stein, Lakeesha Carmichael, Jens Eickhoff, Susan A. Johnston, Kimberly A. Binger, Jennifer L. Heideman, Scott B. Perlman, Robert Jeraj, Glenn Liu
Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers
Jennifer J. Wheler, Filip Janku, Gerald S. Falchook, Tiffiny L. Jackson, Siqing Fu, Aung Naing, Apostalia M. Tsimberidou, Stacy L. Moulder, David S. Hong, Hui Yang, Sarina A. Piha-Paul, Johnique T. Atkins, Guillermo Garcia-Manero, Razelle Kurzrock
Intravesical thermo-chemotherapy based on conductive heat: a first pharmacokinetic study with Mitomycin C in superficial transitional cell carcinoma patients
Paola Milla, Chiara Fiorito, Francesco Soria, Silvia Arpicco, Luigi Cattel, Paolo Gontero
Phase 1 and dose-finding study of patritumab (U3-1287), a human monoclonal antibody targeting HER3, in Japanese patients with advanced solid tumors
Hiroshi Wakui, Noboru Yamamoto, Shinji Nakamichi, Yousuke Tamura, Hiroshi Nokihara, Yasuhide Yamada, Tomohide Tamura
Age affects pegylated liposomal doxorubicin elimination and tolerability in patients over 70 years old
Milena Gusella, Antonio Bononi, Yasmina Modena, Laura Bertolaso, Paola Franceschetti, Daniela Menon, Elisa Pezzolo, Carmen Barile, Giorgio Crepaldi, Caterina Bolzonella, Alessandro Inno, Roberto Padrini, Felice Pasini
Patient-derived xenografts reveal limits to PI3K/mTOR- and MEK-mediated inhibition of bladder cancer
Pasquale Cirone, Catharine J. Andresen, Jeetendra R. Eswaraka, Patrick B. Lappin, Cedo M. Bagi
Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors
Edward Sausville, Patricia LoRusso, Michael Carducci, Judith Carter, Mary F. Quinn, Lisa Malburg, Nilofer Azad, David Cosgrove, Richard Knight, Peter Barker, Sonya Zabludoff, Felix Agbo, Patricia Oakes, Adrian Senderowicz
UGT1A1*6 polymorphisms are correlated with irinotecan-induced toxicity: a system review and meta-analysis in Asians
Lei Cheng, Ming Li, Jing Hu, Wei Ren, Li Xie, Zhan-Peng Sun, Bao-Rui Liu, Gen-Xing Xu, Xiao-Liang Dong, Xiao-Ping Qian
Phase I dosage finding and pharmacokinetic study of intravenous topotecan and oral erlotinib in adults with refractory solid tumors
Clinton F. Stewart, Michael Tagen, Lee S. Schwartzberg, L. Johnetta Blakely, Kurt W. Tauer, Linda M. Smiley
shRNA-mediated silencing of ZFX attenuated the proliferation of breast cancer cells
Hongjian Yang, Yue Lu, Yabing Zheng, Xingfei Yu, Xianghou Xia, Xiangming He, Weiliang Feng, Lei Xing, Zhiqiang Ling
First-in-human, phase I dose-escalation study of single and multiple doses of a first-in-class enhancer of fluoropyrimidines, a dUTPase inhibitor (TAS-114) in healthy male volunteers
Kaku Saito, Hirotaka Nagashima, Kazuharu Noguchi, Kunihiro Yoshisue, Tatsushi Yokogawa, Eiji Matsushima, Takeshi Tahara, Shigeru Takagi
High-dose vitamin B1 reduces proliferation in cancer cell lines analogous to dichloroacetate
Bradley S. Hanberry, Ryan Berger, Jason A. Zastre
A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFRα) monoclonal antibody, in patients with advanced solid tumors
E. Gabriela Chiorean, Christopher Sweeney, Hagop Youssoufian, Amy Qin, Aruna Dontabhaktuni, Nick Loizos, Johannes Nippgen, Robert Amato
Intraperitoneal paclitaxel induces regression of peritoneal metastasis partly by destruction of peripheral microvessels
Joji Kitayama, Shigenobu Emoto, Hironori Yamaguchi, Hironori Ishigami, Toshiaki Watanabe
The effect of rifampicin, a prototypical CYP3A4 inducer, on erlotinib pharmacokinetics in healthy subjects
Marta Hamilton, Julie L. Wolf, Daniel W. Drolet, Scott H. Fettner, Ashok K. Rakhit, Karsten Witt, Bert L. Lum
An open-label, dose-escalation, safety, and pharmacokinetics phase I study of ombrabulin, a vascular disrupting agent, administered as a 30-min intravenous infusion every 3 weeks in Japanese patients with advanced solid tumors
H. Murakami, T. Kurata, Y. Onozawa, J. Watanabe, A. Ono, T. Takahashi, N. Yamamoto, Y. Fujisaka, H. Kiyota, H. Hayashi, K. Tanaka, K. Nakagawa, S. Kuroda
Increased serum level of epidermal growth factor receptor (EGFR) is associated with poor progression-free survival in patients with epithelial ovarian cancer
Faruk Tas, Senem Karabulut, Murat Serilmez, Rumeysa Ciftci, Derya Duranyildiz
Efficacy against subcutaneous or intracranial murine GL261 gliomas in relation to the concentration of the vascular-disrupting agent, 5,6-dimethylxanthenone-4-acetic acid (DMXAA), in the brain and plasma
Raymond Yung, Vahid Seyfoddin, Christopher Guise, Sofian Tijono, Ailsa McGregor, Bronwen Connor, Lai-Ming Ching
CYP2C19 genotype–phenotype discordance in patients with multiple myeloma leads to an acquired loss of drug-metabolising activity
K. E. Burns, M. A. Goldthorpe, F. Porteus, P. Browett, N. A. Helsby